Skip Nav Destination
Issues
1 December 2023
-
Cover Image
Cover Image
CLDN18.2-307-mAb and CLDN18.2-307-ADC selectively kill CLDN18.2+ cancer cells through independent mechanisms of action. Binding of CLDN18.2-307-mAb to cell surface CLDN18.2 induces an ADCC response against the host cells whereas internalization of CLDN18.2-307-ADC selectively releases the cytotoxic MMAE payload. Read the full article on page 1365. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
First Disclosures
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
Neil A. O'Brien; Martina S.J. McDermott; Jun Zhang; Ke Wei Gong; Ming Lu; Benjamin Hoffstrom; Tong Luo; Raul Ayala; Kevin Chau; Min Liang; Athena M. Madrid; Timothy R. Donahue; John A. Glaspy; Leonard Presta; Dennis J. Slamon
Small Molecule Therapeutics
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor
Kathryn M. Lemberg; Eunus S. Ali; Marcela Krecmerova; Joanna Marie H. Aguilar; Jesse Alt; Diane E. Peters; Liang Zhao; Ying Wu; Naziba Nuha; John M. Asara; Verena Staedtke; Christine A. Pratilas; Pavel Majer; Rana Rais; Issam Ben-Sahra; Barbara S. Slusher
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
Levent Mutlu; Diego D. Manavella; Stefania Bellone; Blair McNamara; Justin A. Harold; Dennis Mauricio; Eric R. Siegel; Natalia Buza; Pei Hui; Tobias Max Philipp Hartwich; Yang Yang-Hartwich; Cem Demirkiran; Miguel Skyler Z. Verzosa; Gary Altwerger; Elena S. Ratner; Gloria S. Huang; Mitchell Clark; Vaagn Andikyan; Masoud Azodi; Peter R. Dottino; Peter E. Schwartz; Alessandro D. Santin
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
Husain Yar Khan; Misako Nagasaka; Amro Aboukameel; Osama Alkhalili; Md. Hafiz Uddin; Sahar F. Bannoura; Yousef Mzannar; Ibrahim Azar; Eliza W. Beal; Miguel E. Tobon; Steve H. Kim; Rafic Beydoun; Erkan Baloglu; William Senapedis; Bassel F. El-Rayes; Philip A. Philip; Ramzi M. Mohammad; Anthony F. Shields; Mohammed Najeeb Al Hallak; Asfar S. Azmi
Large Molecule Therapeutics
SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Robert P. Lyon; Mechthild Jonas; Christopher Frantz; Esther S. Trueblood; Roma Yumul; Lori Westendorf; Christopher J. Hale; Jackie L. Stilwell; Narayana Yeddula; Katie M. Snead; Vineet Kumar; Gabriela I. Patilea-Vrana; Kerry Klussman; Maureen C. Ryan
FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment
Susumu Shimoyama; Ken Okada; Toshifumi Kimura; Yasushi Morohashi; Shinji Nakayama; Sayaka Kemmochi; Keiko Makita-Suzuki; Ursula A. Matulonis; Mikinaga Mori
Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
Barbara Valsasina; Paolo Orsini; Michele Caruso; Clara Albanese; Antonella Ciavolella; Ulisse Cucchi; Ivan Fraietta; Nicola Melillo; Francesco Fiorentini; Simona Rizzi; Matteo Salsa; Antonella Isacchi; Fabio Gasparri
Targeting Drug Resistance
EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma
Bin Shen; Jue-Ping Shi; Zhi-Xuan Zhu; Zhi-Dong He; Shen-Yan Liu; Wan Shi; Yong-Xian Zhang; Hai-Yan Ying; Jie Wang; Rui-Feng Xu; Fei Fang; Harrison Xuesong Chang; Zhui Chen; Nan-Nan Zhang
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds